Pharmacogenetics of dabigatran etexilate interindividual variability.

[1]  T. Steiner,et al.  Idarucizumab for Dabigatran Reversal. , 2015, The New England journal of medicine.

[2]  S. Goldhaber,et al.  Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.

[3]  J. Badimón,et al.  Pathophysiology of Acute Coronary Syndrome , 2014, Current Atherosclerosis Reports.

[4]  S. Yusuf,et al.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). , 2014, Journal of the American College of Cardiology.

[5]  Marsha E Reichman,et al.  Dabigatran and postmarketing reports of bleeding. , 2013, The New England journal of medicine.

[6]  S. Yusuf,et al.  Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding , 2013, Circulation.

[7]  D. Angiolillo,et al.  Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[8]  S. Goldhaber,et al.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. , 2013, The New England journal of medicine.

[9]  J. O’Connell,et al.  The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response , 2013, Pharmacogenetics and genomics.

[10]  V. Fuster,et al.  Platelet function normalization after a prasugrel loading‐dose: time‐dependent effect of platelet supplementation , 2013, Journal of thrombosis and haemostasis : JTH.

[11]  S. Yusuf,et al.  Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial , 2011, Journal of thrombosis and haemostasis : JTH.

[12]  V. Willey,et al.  A Patient's Guide to Taking Dabigatran Etexilate. , 2011, Circulation.

[13]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.

[14]  J. Badimón,et al.  Thrombi of Different Pathologies: Implications for Diagnosis and Treatment , 2010, Current Treatment Options in Cardiovascular Medicine.

[15]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[16]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[17]  A. Clemens,et al.  Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[18]  T. Ebner,et al.  The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans , 2008, Drug Metabolism and Disposition.

[19]  K. Rathgen,et al.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.

[20]  L. Chinn,et al.  ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise , 2007, Clinical pharmacology and therapeutics.

[21]  B. Eriksson,et al.  Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. , 2006, British journal of clinical pharmacology.

[22]  H. Büller,et al.  A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial , 2005, Journal of thrombosis and haemostasis : JTH.

[23]  G. Hankey,et al.  Dabigatran Etexilate A New Oral Thrombin Inhibitor , 2011 .

[24]  S. Franceschi,et al.  Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. , 2004, Haematologica.